NASDAQ:ACOR - Acorda Therapeutics Stock Price, News & Analysis

$2.70
+0.08 (+3.05 %)
(As of 08/18/2019 01:17 AM ET)
Today's Range
$2.60
Now: $2.70
$2.90
50-Day Range
$2.46
MA: $5.79
$7.77
52-Week Range
$2.27
Now: $2.70
$29.75
Volume2.55 million shs
Average Volume1.79 million shs
Market Capitalization$129.90 million
P/E Ratio1.48
Dividend YieldN/A
Beta1.11
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$471.43 million
Cash Flow$2.6733 per share
Book Value$11.32 per share

Profitability

Net Income$33.68 million

Miscellaneous

Employees474
Market Cap$129.90 million
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.


Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) issued its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.18) by $0.53. The biopharmaceutical company earned $50.05 million during the quarter, compared to analysts' expectations of $28.83 million. Acorda Therapeutics had a negative net margin of 25.94% and a negative return on equity of 6.18%. The firm's revenue for the quarter was down 67.4% compared to the same quarter last year. During the same period last year, the firm posted $1.40 earnings per share. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Acorda Therapeutics.

What price target have analysts set for ACOR?

10 equities research analysts have issued 12 month price targets for Acorda Therapeutics' stock. Their predictions range from $6.00 to $30.00. On average, they anticipate Acorda Therapeutics' stock price to reach $13.2222 in the next twelve months. This suggests a possible upside of 389.7% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.

What is the consensus analysts' recommendation for Acorda Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 2 sell ratings, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019)
  • 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating but raise our price target on ACOR to $20 from $19. On Thursday, Acorda reported 4Q18 financials and detailed future commercialization plans for Inbrija, including monthly WAC pricing of $950, ~25% higher than our projections. The company reported net Ampyra revenues of $64.2M, higher than consensus $46.8M, reflecting a steep decline from the prior quarter, but clearly not as bad as some expected (we were $75.8M). That said, we anticipate Amp revs to continue to decline and therefore do not include Amp sales in our valuation of ACOR shares. Going forward, we see Acorda’s fate being clearly in the hands of Inbrija for the next phase of growth." (2/15/2019)

Has Acorda Therapeutics been receiving favorable news coverage?

News headlines about ACOR stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acorda Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Acorda Therapeutics.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Applied Materials (AMAT), Gilead Sciences (GILD), Celgene (CELG), Advanced Micro Devices (AMD), Intel (INTC), Micron Technology (MU), Western Digital (WDC) and ACADIA Pharmaceuticals (ACAD).

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.87%), Renaissance Technologies LLC (9.47%), Scopia Capital Management LP (6.91%), Acadian Asset Management LLC (2.36%), Perceptive Advisors LLC (2.34%) and Northern Trust Corp (2.06%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Which major investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Vanguard Group Inc., Man Group plc, Marshall Wace LLP, Prudential Financial Inc., Bank of America Corp DE, Charles Schwab Investment Management Inc. and Jacobs Levy Equity Management Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Lauren M Sabella, Lorin Randall, Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

Which major investors are buying Acorda Therapeutics stock?

ACOR stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Renaissance Technologies LLC, AXA, Diamond Hill Capital Management Inc., Acadian Asset Management LLC, Sofinnova Investments Inc., Point72 Asset Management L.P. and Teacher Retirement System of Texas. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $2.70.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $129.90 million and generates $471.43 million in revenue each year. The biopharmaceutical company earns $33.68 million in net income (profit) each year or $1.82 on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.View Additional Information About Acorda Therapeutics.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is http://www.acorda.com/.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  507 (Vote Underperform)
Total Votes:  890
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel